- Vast potential of mushroom medicine market is hindered by lack of pharma-grade extracts preventing brands from seizing this market opportunity
- Traditional extract producers limited by low-volume, non-scalable manufacturing methods
- Pure Extracts equipped to produce urgently needed pharma-grade psilocybin
Pure Extracts, a Canadian plant-based extraction company operating in the functional medicinal mushrooms space, is in a unique position to become the dominant extraction company and a leader in the rapid development and commercialization of functional medicine products. With its substantial experience and technical competence in plant extraction creating a distinctive competitive advantage, Pure Extracts is focused on becoming a critical partner with companies developing powerful mushroom products.
As a growing body of research substantiates that psilocybin offers benefits in the treatment of depression, PTSD, anxiety, bi-polar, drug and alcohol addiction, obesity, narcolepsy, OCD, Alzheimer’s and ADHD, an increasing number of companies are looking into expanding into this space to develop products to treat these conditions (http://ibn.fm/oxiSy). However, those companies lack the high purity psilocybin compounds required for the requisite clinical trials and research needed to harness the power of this global market.
Few companies in the extraction space can deliver on this urgent need. Most providers in the space are unable to develop pharmaceutical-grade compounds because their manufacturing methods are low volume and non-scalable. This has created a significant gap in the market and presents a tremendous growth opportunity for companies designed to seize it. This is where Pure Extracts steps in.
Pure Extracts provides high-grade extracts for functional mushroom products such as tinctures and soft gels with the plan to roll out beverage formulations, nasal and oral sprays, as well as psilocybin extracts by H1 2021 H1 2021 (http://ibn.fm/Jxe5m). Determined to leverage the momentum of the psychedelic and functional mushroom industries as one of the fastest-growing sectors in North America, Pure Extracts represents a unique value proposition in this expanding sector that requires extraction for product development.
With its proven expertise and EU Good Manufacturing Practices (“GMP”) designed facility for licensed extraction, Pure Extracts offers a clear competitive advantage. In a space where product purity is equal to product quality, the Company employs the most technologically advanced equipment required for full-spectrum CO2 extraction, a novel process for extracting the essence of the source material where the gas helps to extract oils of high-grade purity from the biomass. As the first of its kind, Pure Extracts is a nationally recognized brand that leverages five years of volatile plant molecule extraction experience and expertise in creating a number of successful CPG products with proven processes for delivering superior extracts.
Pure Extracts has ambitious plans to leverage its competitive advantage beyond North America and place itself as an extraction manufacturer of choice for functional and psychedelic medicine companies across the world. The company plans to apply for a Dealer’s License with Health Canada, which will enable it to produce extracts of the highest quality for clinical trials in an EU GMP environment, fueling its overseas expansion.
In addition, Pure Extracts’ location within the highly regarded Canadian regulatory framework allows for easy export from Canada to destinations across the world. This enables the Company to position itself as a natural international partner for psychedelic and functional product companies looking for pharmaceutical-grade psilocybin for their clinical trials and research.
For more information, visit the company’s website at www.PureExtractsCorp.com.
NOTE TO INVESTORS: The latest news and updates relating to Pure Extracts are available in the company’s newsroom at http://ibn.fm/Pure
About PsychedelicNewsWire
PsychedelicNewsWire (PNW) is a specialized content distribution company that (1) aggregates and distributes news and information on the latest developments in all aspects and advances of psychedelics and their use, (2) creates PsychedelicNewsBreaks designed to quickly update investors on important industry news, (3) leverages a team of expert editors to enhance press releases for maximum impact, (4) assists companies with the management and optimization of social media across a range of platforms, and (5) delivers unparalleled corporate communication solutions. PNW stays abreast of the latest information and has established a reputation as the go to source for coverage of psychedelics, therapeutics and emerging market opportunities. Our team of seasoned journalists has a proven track record of helping both public and private companies gain traction with a wide audience of investors, consumers, media outlets and the general public by leveraging our expansive dissemination network of more than 5,000 key syndication outlets. PNW is committed to delivering improved visibility and brand recognition to companies operating in the emerging markets of psychedelics.
To receive instant SMS alerts, text “Groovy” to 21000 (U.S. Mobile Phones Only)
For more information please visit https://www.PsychedelicNewsWire.com
Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.PsychedelicNewsWire.com/Disclaimer
Do you have questions or are you interested in working with PNW? Ask our Editor
PsychedelicNewsWire (PNW)
San Francisco, California
www.PsychedelicNewsWire.com
415.949.5050 Office
Editor@PsychedelicWire.com
PsychedelicNewsWire is part of the InvestorBrandNetwork.